These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7572417)

  • 21. Human complement regulatory proteins expressed in transgenic swine protect swine xenografts from humoral injury.
    McCurry KR; Diamond LE; Kooyman DL; Byrne GW; Martin MJ; Logan JS; Platt JL
    Transplant Proc; 1996 Apr; 28(2):758. PubMed ID: 8623384
    [No Abstract]   [Full Text] [Related]  

  • 22. The xenoantibody response and immunoglobulin gene expression profile of cynomolgus monkeys transplanted with hDAF-transgenic porcine hearts.
    Zahorsky-Reeves JL; Kearns-Jonker MK; Lam TT; Jackson JR; Morris RE; Starnes VA; Cramer DV
    Xenotransplantation; 2007 Mar; 14(2):135-44. PubMed ID: 17381688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of hyperacute rejection by phosphatidylinositol-anchored factor I.
    Yoshitatsu M; Miyagawa S; Murase A; Matsunami K; Yamada M; Sawa Y; Ohtake S; Matsuda H; Shirakura R
    Transplant Proc; 2000 Aug; 32(5):905-6. PubMed ID: 10936267
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of human CD59 antigen in discordant xenotransplantation between humans and nonprimates.
    Akami T; Arakawa K; Okamoto M; Sawada R; Naruto M; Oka T
    Transplant Proc; 1993 Feb; 25(1 Pt 1):394-5. PubMed ID: 7679814
    [No Abstract]   [Full Text] [Related]  

  • 25. Kidneys derived from mice transgenic for human complement blockers are protected in an in vivo model of hyperacute rejection.
    Lazzeri M; Mora M; Mulder LC; Marsicano G; Marinucci G; Boschi M; Bruzzone P; Alfani D; Cortesini R; Rossini M
    J Urol; 1998 Apr; 159(4):1364-9. PubMed ID: 9507885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted in vivo gene transfection modulated hyperacute rejection of pig lungs perfused with human blood.
    Pierson RN; Conary JT; Langford G; White DG; Brigham KL; Parker RE
    Transplant Proc; 1996 Apr; 28(2):763. PubMed ID: 8623389
    [No Abstract]   [Full Text] [Related]  

  • 27. Cytoprotective effect of CD59 antigen on xenotransplantation immunity.
    Akami T; Sawada R; Minato N; Naruto M; Yamada A; Imanishi J; Mitsuo M; Nakai I; Okamoto M; Nakajima H
    Transplant Proc; 1992 Apr; 24(2):485-7. PubMed ID: 1373542
    [No Abstract]   [Full Text] [Related]  

  • 28. Synergistic effects on the inhibition of human CD8+ cytotoxic T lymphocytes-mediated killing against xenograft cells by coexpression of membrane-bound Human FasL and decoy Fas antigen.
    Tanemura M; Kawamoto K; Ito T; Uchikoshi F; Shimada K; Nishida T; Matsuda H
    Transplant Proc; 2005 Dec; 37(10):4607-9. PubMed ID: 16387181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of hyperacute xenograft rejection by intravenous immunoglobulin.
    Magee JC; Collins BH; Harland RC; Bollinger RR; Frank MM; Platt JL
    Transplant Proc; 1995 Feb; 27(1):271. PubMed ID: 7878999
    [No Abstract]   [Full Text] [Related]  

  • 30. Generation of a felinized swine endothelial cell line by expression of feline decay-accelerating factor.
    Izuhara L; Tatsumi N; Miyagawa S; Iwai S; Watanabe M; Yamanaka S; Katsuoka Y; Nagashima H; Okano HJ; Yokoo T
    PLoS One; 2015; 10(2):e0117682. PubMed ID: 25671605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethical considerations in clinical cardiac xenografting.
    Pierson RN; White DJ; Wallwork J
    J Heart Lung Transplant; 1993; 12(5):876-8. PubMed ID: 7694655
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention of hyperacute rejection by phosphatidylinositol-anchored mini-complement receptor type 1.
    Mikata S; Miyagawa S; Yoshitatsu M; Ikawa M; Okabe M; Matsuda H; Shirakura R
    Transpl Immunol; 1998 Jun; 6(2):107-10. PubMed ID: 9777699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transplantation of MCP cardiac xenografts into baboon recipients.
    Kadner A; Chen RH; Farivar RS; Santerre D; Adams DH
    Transplant Proc; 2001; 33(1-2):770-2. PubMed ID: 11267062
    [No Abstract]   [Full Text] [Related]  

  • 34. Human CD46 but not CD59 in transgenic mice protects against hyperacute rejection evoked by ex vivo perfusion with human serum.
    Marquet RL; van Stijn I; van den Tol PM; Bonthuis F; Yannoutsos N; IJzermans JN
    Transplant Proc; 1997; 29(1-2):931-2. PubMed ID: 9123592
    [No Abstract]   [Full Text] [Related]  

  • 35. Hyperacute xenograft rejection is not consistent after pig to primate solid organ transplantation.
    Winkler M; Loss M; Klempnauer J
    Transplantation; 2001 Feb; 71(4):584-5. PubMed ID: 11258444
    [No Abstract]   [Full Text] [Related]  

  • 36. Hyperacute rejection models: ex vivo xenoperfusion systems.
    Grinyo JM; Cruzado JM; Torras J
    Transplant Proc; 1999; 31(1-2):970-1. PubMed ID: 10083432
    [No Abstract]   [Full Text] [Related]  

  • 37. New ways to avoid organ rejection buoy hopes.
    Roush W
    Science; 1995 Oct; 270(5234):234-5. PubMed ID: 7569970
    [No Abstract]   [Full Text] [Related]  

  • 38. Steroid attenuation of hyperacute pulmonary xenograft rejection.
    Speiller PB; Kikkawa Y; Joseph J; Veith FJ; Cook WA
    Rev Surg; 1973; 30(3):222-4. PubMed ID: 4700593
    [No Abstract]   [Full Text] [Related]  

  • 39. Hyperacute rejection: fact or fancy.
    Platt JL
    Transplantation; 2000 Mar; 69(6):1034-5. PubMed ID: 10762203
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic engineering of the donor species to control hyperacute xenograft rejection.
    White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J
    Adv Nephrol Necker Hosp; 1995; 24():331-40. PubMed ID: 7572417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.